Congress’s Routine of Publicly Shaming Drug Company Executives Over High Prices Works No Better Than a Placebo

November 16, 2016

(Associated Press) – Congress’s routine of publicly shaming drug company executives over high prices works no better than a placebo: It may make some people feel better, but it doesn’t treat the problem. In the last two years, House and Senate committees issued more than a dozen subpoenas to price-hiking drugmakers, collecting hundreds of thousands of documents and berating executives for more than 16 hours of public hearings. But a review by The Associated Press of the list prices of nearly 30 brand-name medications and generic versions targeted by congressional investigators shows most haven’t budged since coming under federal scrutiny, according to figures from Truven Health Analytics.

Posted by

Posted in News, Pharma, Public Policy

Recommended Reading